{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:26:19Z","timestamp":1793067979040,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.breast.2025.104425","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:55:52Z","timestamp":1739901352000},"page":"104425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis"],"prefix":"10.1016","volume":"80","author":[{"given":"Eva L.","family":"Claassens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne A.W.","family":"Ploumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes F.S.","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje A.C.E.","family":"van Kats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiemo J.A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.breast.2025.104425_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/bjs\/znad103","article-title":"Neoadjuvant systemic therapy for breast cancer","volume":"110","author":"Zaborowski","year":"2023","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.breast.2025.104425_bib2","first-page":"1027","article-title":"The intraductal component of breast cancer is poorly responsive to neo-adjuvant chemotherapy","volume":"9","author":"Wu","year":"2002","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.breast.2025.104425_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","article-title":"Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study","volume":"158","author":"Doebar","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2025.104425_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-023-07012-z","article-title":"Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis","volume":"201","author":"Ploumen","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"10.1016\/j.breast.2025.104425_bib5","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1007\/s00432-023-04895-9","article-title":"Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ","volume":"149","author":"Liu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9938","key":"10.1016\/j.breast.2025.104425_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.breast.2025.104425_bib7","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","article-title":"Overall survival is improved when DCIS accompanies invasive breast cancer","volume":"9","author":"Kole","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.breast.2025.104425_bib8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/jcp.26103","article-title":"Neoadjuvant chemotherapy in triple-negative breast cancer: a multicentric retrospective observational study in real-life setting","volume":"233","author":"Gamucci","year":"2018","journal-title":"J Cell Physiol"},{"issue":"23","key":"10.1016\/j.breast.2025.104425_bib9","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-18-0585","article-title":"Pathological response and survival in triple-negative breast cancer following neoadjuvant Carboplatin plus docetaxel","volume":"24","author":"Sharma","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2025.104425_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/oncolo\/oyab003","article-title":"Early-stage triple-negative breast cancer: time to optimize personalized strategies","volume":"27","author":"Abuhadra","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.breast.2025.104425_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2025.104425_bib12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.breast.2025.104425_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/bjs.10755","article-title":"Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer","volume":"105","author":"van la Parra","year":"2018","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.breast.2025.104425_bib14","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"key":"10.1016\/j.breast.2025.104425_bib15","series-title":"Treatment of breast cancer","year":"2017"},{"issue":"3","key":"10.1016\/j.breast.2025.104425_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/bjc.1957.43","article-title":"Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years","volume":"11","author":"Bloom","year":"1957","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.breast.2025.104425_bib17","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104425_bib18","series-title":"Flexible imputation of missing data","author":"Sv","year":"2018"},{"issue":"2","key":"10.1016\/j.breast.2025.104425_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020235","article-title":"The presence of an in situ component on pre-treatment biopsy is not associated with response to neoadjuvant chemotherapy for breast cancer","volume":"13","author":"Labrosse","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.breast.2025.104425_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10549-021-06235-2","article-title":"Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer","volume":"189","author":"Groen","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.breast.2025.104425_bib21","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1245\/s10434-019-07533-2","article-title":"Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy","volume":"26","author":"Sun","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.breast.2025.104425_bib22","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.bjc.6605655","article-title":"Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer","volume":"102","author":"Wong","year":"2010","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2025.104425_bib23","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/MS9.0000000000000607","article-title":"Quality of life of breast cancer survivors: a comparison of breast conserving surgery versus total mastectomy with and without immediate reconstruction: a prospective cohort study","volume":"85","author":"Vohra","year":"2023","journal-title":"Ann Med Surg (Lond)."},{"issue":"6","key":"10.1016\/j.breast.2025.104425_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2022.0631","article-title":"Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction","volume":"157","author":"Hanson","year":"2022","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.breast.2025.104425_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/02841860510007413","article-title":"Quality of treatment in routine care in a population sample of rectal cancer patients","volume":"44","author":"Engel","year":"2005","journal-title":"Acta Oncol"},{"issue":"8","key":"10.1016\/j.breast.2025.104425_bib26","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1007\/s00330-023-09547-7","article-title":"Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis","volume":"33","author":"Ploumen","year":"2023","journal-title":"Eur Radiol"},{"issue":"6","key":"10.1016\/j.breast.2025.104425_bib27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1524-4741.2007.00513.x","article-title":"BI-RADS MRI enhancement characteristics of ductal carcinoma in situ","volume":"13","author":"Rosen","year":"2007","journal-title":"Breast J"},{"issue":"9","key":"10.1016\/j.breast.2025.104425_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162740","article-title":"Dual-energy contrast-enhanced spectral mammography: enhancement analysis on BI-rads 4 non-mass microcalcifications in screened women","volume":"11","author":"Cheung","year":"2016","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.breast.2025.104425_bib29","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762500044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762500044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T23:42:24Z","timestamp":1742341344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762500044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"alternative-id":["S096097762500044X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104425","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104425"}}